TY - JOUR
T1 - Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma
AU - Verhoeff, Sarah R
AU - van Es, Suzanne C
AU - Boon, Eline
AU - van Helden, Erik
AU - Angus, Lindsay
AU - Elias, Sjoerd G
AU - Oosting, Sjoukje F
AU - Aarntzen, Erik H
AU - Brouwers, Adrienne H
AU - Kwee, Thomas C
AU - Heskamp, Sandra
AU - Hoekstra, Otto S
AU - Verheul, Henk
AU - van der Veldt, Astrid A M
AU - de Vries, Elisabeth G E
AU - Boerman, Otto C
AU - van der Graaf, Winette T A
AU - Oyen, Wim J G
AU - van Herpen, Carla M L
N1 - Funding Information:
This work was supported by the Dutch Cancer Society (Alpe d?HuZes Grant RUG 2012-5400).
Funding Information:
This work was supported by the Dutch Cancer Society (Alpe d’HuZes Grant RUG 2012-5400).
Publisher Copyright:
© 2019, The Author(s).
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Purpose: The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [ 89Zr]Zr-DFO-girentuximab-PET/CT and [ 18F]FDG-PET/CT in detecting ccRCC lesions in patients with a good or intermediate prognosis metastatic clear cell renal cell carcinoma (mccRCC) according to the International Metastatic Database Consortium (IMDC) risk model. Methods: Between February 2015 and March 2018, 42 newly diagnosed mccRCC patients with good or intermediate prognosis, eligible for watchful waiting, were included. Patients underwent CT, [ 89Zr]Zr-DFO-girentuximab-PET/CT and [ 18F]FDG-PET/CT at baseline. Scans were independently reviewed and lesions of ≥10 mm and lymph nodes of ≥15 mm at CT were analyzed. For lesions with [ 89Zr]Zr-DFO-girentuximab or [ 18F]FDG-uptake visually exceeding background uptake, maximum standardized uptake values (SUV max) were measured. Results: A total of 449 lesions were detected by ≥1 modality (median per patient: 7; ICR 4.25–12.75) of which 42% were in lung, 22% in lymph nodes and 10% in bone. Combined [ 89Zr]Zr-DFO-girentuximab-PET/CT and CT detected more lesions than CT alone: 91% (95%CI: 87–94) versus 56% (95%CI: 50–62, p = 0.001), respectively, and more than CT and [ 18F]FDG-PET/CT combined (84% (95%CI:79–88, p < 0.005). Both PET/CTs detected more bone and soft tissue lesions compared to CT alone. Conclusions: The addition of [ 89Zr]Zr-DFO-girentuximab-PET/CT and [ 18F]FDG-PET/CT to CT increases lesion detection compared to CT alone in newly diagnosed good and intermediate prognosis mccRCC patients eligible for watchful waiting.
AB - Purpose: The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [ 89Zr]Zr-DFO-girentuximab-PET/CT and [ 18F]FDG-PET/CT in detecting ccRCC lesions in patients with a good or intermediate prognosis metastatic clear cell renal cell carcinoma (mccRCC) according to the International Metastatic Database Consortium (IMDC) risk model. Methods: Between February 2015 and March 2018, 42 newly diagnosed mccRCC patients with good or intermediate prognosis, eligible for watchful waiting, were included. Patients underwent CT, [ 89Zr]Zr-DFO-girentuximab-PET/CT and [ 18F]FDG-PET/CT at baseline. Scans were independently reviewed and lesions of ≥10 mm and lymph nodes of ≥15 mm at CT were analyzed. For lesions with [ 89Zr]Zr-DFO-girentuximab or [ 18F]FDG-uptake visually exceeding background uptake, maximum standardized uptake values (SUV max) were measured. Results: A total of 449 lesions were detected by ≥1 modality (median per patient: 7; ICR 4.25–12.75) of which 42% were in lung, 22% in lymph nodes and 10% in bone. Combined [ 89Zr]Zr-DFO-girentuximab-PET/CT and CT detected more lesions than CT alone: 91% (95%CI: 87–94) versus 56% (95%CI: 50–62, p = 0.001), respectively, and more than CT and [ 18F]FDG-PET/CT combined (84% (95%CI:79–88, p < 0.005). Both PET/CTs detected more bone and soft tissue lesions compared to CT alone. Conclusions: The addition of [ 89Zr]Zr-DFO-girentuximab-PET/CT and [ 18F]FDG-PET/CT to CT increases lesion detection compared to CT alone in newly diagnosed good and intermediate prognosis mccRCC patients eligible for watchful waiting.
KW - CAIX
KW - Clear cell renal cell carcinoma
KW - FDG
KW - Girentuximab
KW - Imaging
KW - PET
UR - https://www.scopus.com/pages/publications/85067044212
U2 - 10.1007/s00259-019-04358-9
DO - 10.1007/s00259-019-04358-9
M3 - Article
C2 - 31172212
SN - 1619-7070
VL - 46
SP - 1931
EP - 1939
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
IS - 9
ER -